Maruho to Distribute STROMECTOL in Japan.Tokyo, Japan, Feb 16, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Maruho announced on February 15 that it has signed a distribution agreement with US company Merck for STROMECTOL Tablets 2mg, an orphan drug used in the treatment of intestinal strongyloidiasis strongyloidiasis /stron·gy·loi·di·a·sis/ (stron?ji-loi-di´ah-sis) infection with Strongyloides stercoralis. In the small intestine it causes mucosal ulceration and diarrhea. In the lungs it causes hemorrhaging. . Maruho will begin marketing the agent in early April. Accordingly, the current distributor Banyu Pharmaceutical will stop sales of STROMECTOL. However, Banyu Pharmaceutical, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Merck, continues to approve the manufacture and sale of the agent. STROMECTOL, which was developed by Merck, has been marketed in Japan since December 2002. Currently, Banyu Pharmaceutical is seeking approval for additional indication of the agent, namely the treatment of scabies scabies (skā`bēz), highly contagious parasitic skin disease caused by the itch mite (Sarcoptes scabiei). The disease is also known as itch. . Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion